Sonya Reid1, Sydney Cadiz2, Tuya Pal1. 1. Vanderbilt University Medical Center, Nashville, TN. 2. Meharry Medical College, Nashville, TN.
Abstract
PURPOSE OF REVIEW: Despite a steady improvement in breast cancer survival rates over the past several decades, mortality disparities remain among Black women, who have a 42% higher death rate compared to non-Hispanic white (NHW) women. Hereditary breast cancer (HBC) accounts for 5-10% of all breast cancer cases, the majority of which are due to the BRCA1 and BRCA2 (BRCA) genes. Despite the availability of BRCA testing for over 25 years, there remain disproportionately lower rates of genetic testing among Blacks compared to NHW due to a multitude of factors. The intent of this review is to discuss racial disparities focused on HBC across diverse populations and review the existing gaps to be addressed when delivering gene-based care. RECENT FINDINGS: The factors contributing to the racial survival disparity are undoubtedly complex and likely an interplay between tumor biology, genomics, patterns of care and socioeconomic factors. Advances in genomic technologies that now allow for full characterization of germline DNA sequencing are integral in defining the complex and multifactorial cause of breast cancer and may help to explain the existing racial survival disparities. SUMMARY: Identification of inherited cancer risk may lead to cancer prevention, early cancer detection, treatment guidance, and ultimately has great potential to improve outcomes. Consequently, advances in HBC diagnosis and treatment without widespread implementation have the potential to further widen the existing breast cancer mortality gap between Black and NHW women.
PURPOSE OF REVIEW: Despite a steady improvement in breast cancer survival rates over the past several decades, mortality disparities remain among Black women, who have a 42% higher death rate compared to non-Hispanic white (NHW) women. Hereditary breast cancer (HBC) accounts for 5-10% of all breast cancer cases, the majority of which are due to the BRCA1 and BRCA2 (BRCA) genes. Despite the availability of BRCA testing for over 25 years, there remain disproportionately lower rates of genetic testing among Blacks compared to NHW due to a multitude of factors. The intent of this review is to discuss racial disparities focused on HBC across diverse populations and review the existing gaps to be addressed when delivering gene-based care. RECENT FINDINGS: The factors contributing to the racial survival disparity are undoubtedly complex and likely an interplay between tumor biology, genomics, patterns of care and socioeconomic factors. Advances in genomic technologies that now allow for full characterization of germline DNA sequencing are integral in defining the complex and multifactorial cause of breast cancer and may help to explain the existing racial survival disparities. SUMMARY: Identification of inherited cancer risk may lead to cancer prevention, early cancer detection, treatment guidance, and ultimately has great potential to improve outcomes. Consequently, advances in HBC diagnosis and treatment without widespread implementation have the potential to further widen the existing breast cancer mortality gap between Black and NHW women.
Entities:
Keywords:
BRCA; Breast cancer disparities; Genetic counseling; Genetic testing; Hereditary breast cancer; Racial disparities
Authors: Celia Patricia Kaplan; Jennifer S Haas; Eliseo J Pérez-Stable; Steven E Gregorich; Carol Somkin; Genevieve Des Jarlais; Karla Kerlikowske Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-01 Impact factor: 4.254
Authors: Amy P M Finch; Jan Lubinski; Pål Møller; Christian F Singer; Beth Karlan; Leigha Senter; Barry Rosen; Lovise Maehle; Parviz Ghadirian; Cezary Cybulski; Tomasz Huzarski; Andrea Eisen; William D Foulkes; Charmaine Kim-Sing; Peter Ainsworth; Nadine Tung; Henry T Lynch; Susan Neuhausen; Kelly A Metcalfe; Islay Thompson; Joan Murphy; Ping Sun; Steven A Narod Journal: J Clin Oncol Date: 2014-02-24 Impact factor: 44.544
Authors: Claire C Conley; Dana Ketcher; Maija Reblin; Monica L Kasting; Deborah Cragun; Jongphil Kim; Kimlin Tam Ashing; Cheryl L Knott; Chanita Hughes-Halbert; Tuya Pal; Susan T Vadaparampil Journal: J Genet Couns Date: 2020-01-07 Impact factor: 2.537
Authors: Mark Robson; Seock-Ah Im; Elżbieta Senkus; Binghe Xu; Susan M Domchek; Norikazu Masuda; Suzette Delaloge; Wei Li; Nadine Tung; Anne Armstrong; Wenting Wu; Carsten Goessl; Sarah Runswick; Pierfranco Conte Journal: N Engl J Med Date: 2017-06-04 Impact factor: 91.245
Authors: Jonathan M Loree; Seerat Anand; Arvind Dasari; Joseph M Unger; Anirudh Gothwal; Lee M Ellis; Gauri Varadhachary; Scott Kopetz; Michael J Overman; Kanwal Raghav Journal: JAMA Oncol Date: 2019-10-10 Impact factor: 31.777
Authors: Sarah M Lima; Meaghan Nazareth; Karen M Schmitt; Andria Reyes; Elaine Fleck; Gary K Schwartz; Mary Beth Terry; Grace C Hillyer Journal: J Community Genet Date: 2022-10-13
Authors: Vida Henderson; Shaila M Strayhorn; Nyahne Q Bergeron; Desmona C Strahan; Pamela S Ganschow; Aditya S Khanna; Karriem Watson; Kent Hoskins; Yamile Molina Journal: Cancer Control Date: 2022 Jan-Dec Impact factor: 2.339
Authors: Patrick Silva; Deborah Vollmer Dahlke; Matthew Lee Smith; Wendy Charles; Jorge Gomez; Marcia G Ory; Kenneth S Ramos Journal: J Pers Med Date: 2022-04-29